Publications found:
251,903
Sort by:
SUN PHARMA - A structural improvement at play
US$ 140.00
Sun’s Q2 FY12 result was much higher than our and street’s ... after acquisition of 100% stake. We thus rate Sun Pharma as our top pick in the large cap India pharma. We will change our estimate later to incorporate ...
November 2011
7 pages
Lemtrada: Co-primary Endpoints Met in CARE MS II: Ready for filing
US$ 90.00
... alert on Sanofi, after today’s announcement of superior clinical data on Lemtrada from CARE MS II (The Comparison of Alemtuzumab and Rebif Efficacy in ... Sclerosis) study. A cross trial comparisons (Table 1) suggest that Lemtrada should dominate as the most efficacious treatment option, and Ocrelizumab ...
November 2011
4 pages
CADILA HEALTHCARE - Still Carrying The Burden of The High Base Last Year
US$ 140.00
Cadila’s Q2 FY12 result was below our estimate (adjusted to ... for muted growth in markets like India and Emerging Markets, we believe that the growth is still impacted due to the high ... the markets. We thus do not see any structural issues with Cadila. In addition, USFDA approval of its Baddi facility comes as a ...
November 2011
5 pages
DISHMAN - Downward Guidance Revision – No More An Exception
US$ 140.00
Dishman once again reported quarterly result much below our and ... . Thus debt repayment can happened only through asset sale. We revise our FY 12 earnings estimates down by 28%. Consequently we cut our target price ...
November 2011
5 pages
RANBAXY - Moderate Improvement In Base Business
US$ 140.00
We reiterate our Market Perform rating on Ranbaxy after Q3 CY11 result that was largely in line with our ... the low base of EBITDA margin, the improvement was expected to be slightly higher especially as Ranbaxy has shut down most of its loss making ...
November 2011
6 pages
LUPIN - Margin Pressure Highlight The Weakness of US Portfolio
US$ 140.00
... on Lupin after its Q2FY12 result that was largely in line with our estimates. Ex-Medicis milestone income, sales growth (up 17%) and gross margin ... of one per quarter and (3) Suprax growing by 43% Y-o-Y. We believe all these highlights (1) the dependence on generic Lotrel (2) increased sales force expense for ...
November 2011
6 pages
Mature Biotech: 3Q11 Earnings Summary
US$ 90.00
In this note we summarize the 3Q earnings of Mature Biotech – ALXN, AMGN, BIIB, CELG, GILD, and ONXX. We continue to reiterate ... PhIII data in mCRC). For more details, please read our 3Q11 earnings’ summary report released on 4th Nov, 2011 on “Mature Biotech: 3Q11 Earnings Summary”.
November 2011
5 pages
Interacting with KOLs: Fulfilling Current Unmet Needs
US$ 995.00
The symbiotic relationship between key opinion leaders (KOLs) and the pharmaceutical industry is dynamic and ever-changing. But while the industry knows what it wants from KOLs, what do KOLs need from...
October 2011
41 pages
European Markets for Surgical Gowns & Helmets
US$ 4,995.00
... has become much more pivotal to determining the success of a surgical procedure. Today, their use has greater significance, as they not only ... & Acquisitions Customer Feedback and Market Monitoring Main Segments Included: Surgical Gown Market Helmet System Market Companies Included: Stryker DePuy ...
October 2011
104 pages
PHARMASSET - 'IFN-Free Oral Option' for HCV - Not a Virgin Territory Anymore!
US$ 90.00
... ) wave to treat HCV the race to offer the first “IFN free all oral option” seems to have begun. Preliminary data from Abbott’s PhII trial ... ’11 is challenging Pharmasset (VRUS) multiprong approach. For more details, please read our report released on Oct. 24th, 2011 on VRUS titled “IFN-free Oral Option” for ...
October 2011
4 pages
Payer Agreements: Splitting the Risk
US$ 695.00
Budgets are tight. Payer funding for new products is dwindling. And for pharmaceutical companies, market access is more and more difficult to attain.Across the UK, the US, Canada, Australia and parts...
October 2011
41 pages
Pharma Product Launches: Strategies for Success
US$ 595.00
Failed launches. It sounds a bit harsh, yet when it comes to new product launches, that has increasingly been the pharmaceutical industry’s experience since the recession. A tighter economic climate,...
October 2011
30 pages
China Medical Information System Industry Report, 2011
US$ 1,500.00
Status quo of China medical services, including medical resource allocation, medical efficiency and main existing problems;
Policies, construction and investment of China medical information...
October 2011
52 pages
Booming Biotech Market in India
US$ 800.00
Indian biotech sector is witnessing a quantum surge in terms of growth of the industry. The growth can be attributed to a large pool of scientific talent, world-class information technology industry,...
October 2011
100 pages
Brazil Healthcare Market Analysis
US$ 1,000.00
Backed by several factors, such as strong government support and high healthcare demand amongst others are propelling the Brazilian healthcare market to grow at a fast pace. In fact, Brazil can be cla...
October 2011
75 pages
World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition, The
US$ 3,500.00
... Kalorama Information report - The World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition - focuses on several segments for cancer treatment including: ... complete research effort into the oncology treatments market in the past ten years, provides market size information for the various types of ...
October 2011
245 pages
Latino Health and Beauty Care Shopper
US$ 3,500.00
... the market for HBC products in the United States. Over the past decade, spending by Latino consumers on personal care products grew more than 40%, ... consumers of HBC products in the future. Packaged Facts The Latino Health and Beauty Care Shopper provides an in-depth analysis of the grooming and personal ...
October 2011
146 pages
US Medical Imaging Devices Market
US$ 1,000.00
The US has a dominant share in the global medical imaging devices industry. Commercialization of advanced systems, including multi-slice computer tomography (CT), high field magnetic resonance imaging...
October 2011
55 pages
Health Technology Assessment (HTA): a European perspective
US$ 995.00
The bottom line: For payers facing tough financial crunches across Europe, Health Technology Assessment (HTA) is becoming increasingly important. Not only is HTA influencing reimbursement, it is havin...
October 2011
48 pages
Boehringer Ingelheim in Consumer Health (World)
US$ 520.00
... a strong position in consumer health. While other major pharmaceutical companies, such as Bristol-Myers Squibb, are reducing their commitment to consumer products, Boehringer Ingelheim is looking to build its presence. Euromonitor International’s Boehringer Ingelheim in Consumer Health (World) Company ...
October 2011
33 pages
U.S. Market for Dental Prosthetics and CAD/CAM Devices 2011
US$ 7,495.00
... is expected to continue to grow as the number of patients requiring dental prosthetics increases. The market segments covered in this report include: Crowns and ... onlays Veneers Dentures CAD/CAM Systems CAD/CAM Blocks and Prosthetic Devices Intra-Oral Digital Impression-Taking Systems Automated ...
October 2011
275 pages
2012 Biomet Company Profile & Analysis: Biologics Division
US$ 2,995.00
... also expanded into areas such as sports medicine and dental medical devices. Biomet's key joint reconstruction business unit accounted for the bulk of ... medicine and small joint reconstructive surgery were two of the fastest-growing areas for Biomet, both of which continued multi-year trends. However Biomet’s ...
October 2011
64 pages
The US AIDS Diagnostics Market: Test Volumes, Sales Forecasts, and Supplier Shares
US$ 1,480.00
Summary This report presents a detailed analysis of the US AIDS diagnostics market, including test volume and sales forecasts for HIV-1/2, HIV ... , Western Blot and other confirmatory tests performed in the following market segments: Hospitals Commercial/Private Laboratories Blood Banks Physician Offices ...
October 2011
251 pages
French AIDS Diagnostic Market: Test Volumes, Sales Forecasts, and Supplier Shares
US$ 1,000.00
Summary This report presents a detailed analysis of the French AIDS diagnostics market, including test volume and sales forecasts for HIV-1/2, ... /Private Laboratories Blood Banks Physician Offices Public Health Laboratories In addition to test volume and sales projections, the report presents sales and ...
October 2011
251 pages
Boehringer Ingelheim in Consumer Health (Global)
US$ 572.00
Boehringer Ingelheim is a German-based, family-owned pharmaceutical company with a strong position in ... , are reducing their commitment to consumer products, Boehringer Ingelheim is looking to build its presence. Euromonitor International’s Boehringer Ingelheim in Consumer Health (Global) Company Profile offers ...
October 2011
33 pages
Vaccine Pipeline Database: 1-Year Subscription
US$ 1,333.00
Subscription to La Merie’s proprietary Vaccine Pipeline Database provides online access to more than 1,200 project entries for prophylactic and therapeutic vaccines on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use ...
October 2011
274 pages
Competitor Analysis HIV Vaccines
US$ 413.00
... (plasmid, conventional, alternative delivery and prime – boost regimens) Adenoviral vector vaccines Poxvirus vector vaccines Protein & peptide vaccines Others Corporate HIV Vaccine R&D Pipelines About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise ...
October 2011
54 pages
Spinal Surgery: Market Research Report
US$ 4,500.00
... report analyzes the worldwide markets for Spinal Surgery in US$ Million by the following Product Segments: Spinal Fusion Devices, Spinal Fixation Devices, Artificial ... Plc, SpineVision, Stryker Corporation, Synthes Inc., and Zimmer Spine Inc. Market data and analytics are derived from primary and secondary ...
October 2011
411 pages
Autoimmune Disease Therapeutics: Market Research Report
US$ 4,500.00
This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in US$ Million by the following Therapeutic Class: Rheumatoid Arthritis (Biologics), Multiple ... 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 112 companies including many key and niche ...
October 2011
749 pages
